top of page

GLOBAL DEAL SYNDICATION

HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.

UPCOMING SYNDICATION CALL

20210614 MomiBaby logo cropped.jpg

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
Momtech Inc. a.k.a. mōmi

Thursday, April 4, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter: Hal Eason, CEO of mōmi
Complimentary for HBS Angels Members

 

On behalf of the Washington DC chapter, we would like to share the following investment opportunity:

Momtech is commercializing “the breast pump that works like a baby®” and “the bottle that works like a mom®”.  Invented by the former president of the country’s leading breast pump company, these two revolutionary patented technologies solve gaping problems in their respective markets by replicating the biomechanics of natural nursing.

Company

Momtech Inc., under its “mōmi” brand, makes life better for moms and their babies with revolutionary patented products that replicate natural nursing - the “bottle that works like a mom” and the “breast pump that works like a baby”.

 

Background

When Carr Lane Quackenbush retired as president of Medela, the country’s leading breast pump company, he knew the industry had yet to deliver products that biomechanically replicate natural nursing in ways that solve major problems.  He spent the next ten years researching, innovating, prototyping, testing, and patenting these designs.

 

Problem

Today's breast pumps cause painful swelling of the nipple tissue. They are also noisy, cumbersome, and bulky. MIT research found 77% of moms hate their pumps and 60% say their pumps cause pain.

 

Today's baby bottles contribute to nipple confusion, bottle refusal, overfeeding, and regurgitation, because their design does not replicate the basic properties of the natural nipple (solid, soft, stretchable, compression shutoff).  61% of babies have difficulty adapting from nursing to bottle feeding, and 24% of bottle feeders resist returning to natural nursing.

 

Solution

The mōmi “breast pump that works like a baby” is the only pump to replicate natural nursing by applying both positive AND negative pressure to extract milk.  Conventional breast pumps use negative pressure (vacuum) only.  The mōmi pump replicates nursing by incorporating a silicone bladder that replicates the action of the baby’s tongue to extract milk with positive pressure.  This reduces swelling and discomfort.

 

The mōmi “bottle that works like a mom” has a nipple unlike any other on the market.  It’s the only nipple that replicates the physiological properties of the natural: sold, soft, stretchable, and with patented compression shut-off, allowing the baby to regulate the flow of milk naturally with pressure from the tongue.

 

Please see these resources for additional information regarding our technologies:

  1. Medical animation bottle explainer: https://vimeo.com/716455924/db0f1f2e63

  2. Parent testimonials for the bottle: https://vimeo.com/750409034/3ae0c08fef

  3. Breast pump testimonials : https://vimeo.com/750409008/4010ea78fc

 

Commercialization

The mōmi bottle launched at the beginning of 2023 and achieved a $1.2M revenue run rate by August.  At that level, sales had exceeded production capacity.  Management shifted focus toward accelerating the development and launch of an improved 2.0 design, now on track for June / July 2024 launch.  The 2.0 design yields 41% reduction in product COGS, 10x increase in production capacity, and an improved geometry that will dramatically accelerate market adoption.  The mōmi breast pump targets a 2025 launch.

 

Sales to date have been primarily direct to consumer from the company’s online store.  In 2024 the company will begin pursuing distribution through brick-and-mortar retailers.  The company plans to enter global markets through distribution partners.

 

Markets

Baby bottles and breast pumps are a $6B global market growing  >5% annually. 

Initial target segments in the bottle space are (a) affluent households, (b) “natural products” consumers and (c) parents of bottle-refuser babies.  Over time the Company anticipates cost reductions that will enable a price point less than half of its current end-user price.  At that point the serviceable addressable market will include the broad middle of the US market, in addition to global markets. 

 

The design of the 2.0 nipple has been embraced by lactation consultants and other healthcare and infant feeding professionals.  The endorsement of these key influencers will enable mōmi to establish itself as the go-to brand for breastfeeding moms, repositioning our messaging as helping to “establish, restore, strengthen, and preserve” the breastfeeding relationship, moving away from a more problem-solution focus.  With the bottle laying the groundwork of establishing the brand, the breast pump will find ready reception among the same segments.

 

IP

The revolutionary nature of our products is evidenced by our portfolio of 9 issued and 1 pending US patents covering both core technologies, plus numerous international counterparts.

 

Management

  • Hal Eason, CEO/Co-Founder

  • Carr Lane Quackenbush, Inventor / CIO / Co-Founder

  • Kristen Fields, VP of Marketing

  • Meg Alden, MD, Chief Medical Officer

 

Raise

The company is currently raising up to $2M in two series of convertible notes (Series 2024a and 2024b).  Terms of the 2024a offering are:

  • $6M conversion cap

  • 20% conversion discount

  • 10% accruing interest

  • 12/31/2025 maturity

  • Automatic conversion upon qualified preferred equity financing of at least $3M

  • Offering size $600K - $1M

  • Pays greater of (a) 2x principal plus accrued interest and (b) as-if-converted amount, if change of control occurs prior to conversion

 

Series 2024b will be identical in terms except for the conversion cap, TBD.  Maximum total offering across both series is $2M.  Fulcrum Financial Partners of Cary, NC is the company’s earliest institutional investor, and is lead investor in the Series 2024a offering.

20240404 nipple2.0.png

LUPII

MOMTECH

CEO/CO-FOUNDER

20230427 MOMI - Eason.png

HAL EASON

 

Hal Eason is a serial entrepreneur with expertise in commercializing early-stage technologies. His prior startups include ventures in cell therapy and molecular diagnostics, among others. He especially enjoys working with technologies that have the potential to have a positive impact on human health and society.

 

He has also designed and facilitated immersive strategic leadership development experiences for executives of Fortune 100 companies, delivering programs in eighteen countries on five continents.

 

Previously Hal was a private equity strategy consultant with Bain & Company in Boston. He holds an M.B.A. with High Distinction from Harvard Business School, where he also received the John L. Loeb Fellowship in finance.  He also holds a Master of Divinity degree from Southwestern Baptist Theological Seminary and a B.A. from Vanderbilt University in English and mathematics.

 

Hal enjoys travel and dining with his wife, spending time with his two adult sons, playing golf, and mentoring other entrepreneurs through the Winston Starts accelerator in Winston-Salem, North Carolina.

LUPII

20210614 MOMI Quackenbush 200X.jpg

INVENTOR/CIO/CO-FOUNDER

CARR LANE QUACKENBUSH

 

Carr Lane is the inventor of Momtech’s technologies and serves as the company’s Chief Innovation Officer.  Carr Lane is both a Ph.D. engineer and the former president of Medela US, the country’s largest breast pump company.  After retiring from Medela in 2011 he spent the next ten years researching, developing, prototyping, testing, and patenting Momtech’s core technologies.

20240404 Fields- momi.jpg

VP OF MARKETING

KRISTEN FIELDS

 

Kristen joined the company in 2022 as VP of Marketing.  Kristen brings deep experience in marketing premium consumer products to women.  As head of marketing for L’Oréal’s $100M “essie” brand, Kristen grew market share from 12% to 20% over a six-year period.

20240404 Alden - momi.jpg

CHIEF MEDICAL OFFICER

MEG ALDEN, MD

 

Dr. Meg Alden is a practicing pediatrician leading a multi-location clinic with 16 providers.  She is a biomedical engineer by training, and, as mother of 2, has personally experienced the problems that mōmi products solve.

PREVIOUS SYNDICATION CALL

20221117 Agile Devices HIRES_edited.jpg

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
AGILE DEVICES

Thursday, March 14, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter: Ben Merewitz, CEO & Co-Founder of Agile Devices
Complimentary for HBS Angels Members

 

On behalf of the Boston chapter, we would like to share the following return investment opportunity:
 

Agile Devices is a medical device company dedicated to the invention and realization of innovative catheter technologies designed to reduce procedure time, cost, and risk. With a focus on interventional radiology, cardiology and neuroradiology, Agile Devices seeks to deliver these technologies to the marketplace, thus benefiting patients, doctors, and hospitals in the US and around the world.

COMPANY
Agile Devices (www.agiledevices.com) has developed a novel catheter technology designed to reduce interventional procedure time, cost, and risk. Our platform technology features a patented coaxial design for bi-directional deflection without the need for pullwires.
Our flagship product, the Angler® Steerable and Deflectable Microcatheter, was recently FDA-cleared for peripheral and coronary vascular interventions, and subsequently used in a limited release to complete 40 procedures across 9 hospitals, with strong positive physician feedback. Agile Devices has raised ~$3.8MM in investment capital and an additional ~$3.5MM in nondilutive grants.


PROBLEM & SOLUTION
Voice-of-the-customer (VOC) interviews with dozens of interventional radiologists have shown that the biggest problem with existing microcatheters is a lack of active tip control, which leads to increased procedure time, cost, and risk to patient outcomes.
Operators currently rely on torqueable guidewires to access the target vessels and then track the shaped or straight microcatheter over the wire to the target site. They often need to remove and either re-shape or replace the guidewire and/or microcatheter, especially in tortuous anatomy or when targeting multiple sites.


The Agile Devices Angler® deflectable microcatheter gives clinicians all the benefits of a standard microcatheter plus the added ability to actively deflect and steer the distal tip intraoperatively with or without a guide wire in place. This product was developed using Agile Devices’ quality system and using experienced regulatory and quality consultants.

20240314 Agile Illustration Version 2 Fi
20240314 Agile Illustration Version 1 Fi

ANGLER® STEERABLE AND DEFLECTABLE MICROCATHETER - PRODUCT FEATURES

  • Actively bi-directional deflectable and steerable tip, up to 180 degrees in each direction

  • Only requires one configuration and two lengths to allow for radial or femoral access – no need for multiple tip shapes

  • 0.021” I.D. for 0.018” guide wire compatibility, 3F Maximum O.D.

  • Excellent pushability, trackability, and torqueability

  • Delivers diverse agents (beads, glues etc.) just like any other microcatheter

MARKET OPPORTUNITY
The global microcatheter market was estimated to be roughly $800m in 2023, forecasted to grow to more than $1B by 2028 (BCC Research, M&M Research, Agile Devices estimates). The rapid growth of this market is primarily driven by the increasing global incidence of cardiovascular disease, an aging population, and the comprehensive shift to minimally invasive procedures over open surgery. The US, our beachhead geography, is estimated to represent roughly 40% of the global market.


COMPETITORS AND COMPETITIVE ADVANTAGE
The microcatheter space is consolidated, dominated by large medical device companies including Medtronic, Boston Scientific, J&J, and Stryker. Most models are largely undifferentiated, aside from materials, length, and tip shapes. Innovations have been made recently with other deflection technologies, but they are cost-prohibitive for most institutions and/or have functional deficiencies
limiting their commercial potential.


The Angler® has been shown to navigate to a wide range of anatomical targets faster than best-in-class conventional microcatheters (evidenced by bench/animal testing). This functional advantage holds the potential to reduce procedure time, cost, and risk, and increase hospital care capacity and revenue. Our core competitive edge is our coaxial deflection IP/technology that overcomes
limitations of pull-wire and other deflection technologies.

ADDITIONAL MARKET BACKGROUND AND COMMERCIAL STRATEGY
Agile Devices is targeting procedures requiring navigation to multiple targets, OR tortuous vessels in the neuro, coronary, and peripheral vasculature, representing 70%+ of this market, according to our extensive primary research with practicing interventional radiologists, cardiologists, and neuroradiologists. Customers include hospital purchasing teams, office-based lab management
teams, and ambulatory surgical center teams. Purchase decisions are made by committees consisting of administrative leadership and senior interventional physicians at each institution. The market consists of three main segments: neuro, coronary, and peripheral vascular.


Agile Devices has developed the Angler® Steerable and Deflectable Microcatheter cleared for peripheral and coronary vascular use in the US. As we develop further indications of our device and gain positive word-of-mouth validation from early adopter clinicians (through a small set of initial independent direct sales to hospital purchasing managers, aided by our clinical advisory network), we
will primarily look to partner with an established medical device company through a direct acquisition or structured acquisition pathway with milestones/triggers in place. To-date, we have built interest in our device primarily through leveraging our clinical advisors' vast network around the US for introductions and demonstrations. We focus on the value proposition that the device is
designed to reduce procedure time, cost, and risk. Our goal has always been to de-risk the technology from a clinical perspective (with early sales and a monitored launch) as we did from technical and regulatory perspectives, but not build out a formal commercial team prior to exit.


TRACTION

  • FDA clearance for peripheral and coronary vascular interventions (Q1, 2022)

  • Limited Market Evaluation (LME) of 40 procedures at 9 sites around US completed with strong positive physician feedback

  • Next-generation neuro-specific product (NeuroNavTM) nearing Design Select stage (est. Q2, 2024)

  • NeuroNav Design Freeze completed by end of year 2024

  • Significant inbound engagement with major medical device manufacturers interested in this technology


IP PORTFOLIO: NOVEL COAXIAL MICROCATHETER & MICROENDOSCOPE PATENTS
Agile Devices’ patent protected (US 9,233,225) tip deflection mechanism is based on an innovative coaxial design. Agile Devices has designed variable stiffness inner and outer shafts and an ergonomic handle to deflect the distal tip. This patented technology is scalable. Prototypes have been made with both smaller and larger inner and outer diameters. It is also a platform that can be translated for several non-vascular applications, such as GI, ENT, and others that may benefit from deflectable-tip devices.


INTENDED USE
The Agile Devices Angler® Steerable, Deflectable Microcatheter is intended for general intravascular use, including peripheral and coronary vasculature. Once the sub-selective region has been accessed, the microcatheter can be used for the controlled infusion of diagnostic agents and delivery of embolic or therapeutic devices. It is meant to be used only with contrast media and therapeutic
devices that have been cleared or approved for use in the intended target area.


IP PORTFOLIO: NOVEL COAXIAL MICROCATHETER & MICROENDOSCOPE PATENTS
Agile Devices’ patent protected (US 9,233,225) tip deflection mechanism is based on an innovative coaxial design. Agile Devices has designed variable stiffness inner and outer shafts and an ergonomic handle to deflect the distal tip. This patented technology is scalable. Prototypes have been made with both smaller and larger inner and outer diameters. It is also a platform that can be translated for several non-vascular applications, such as GI, ENT, and others that may benefit from deflectable-tip devices.

KEY COMPONENT DETAILS
Inner and Outer Shafts: Both the inner and outer shafts of our coaxial design were designed with a variable stiffness profile (stiffer proximally and softer distally) for optimal pushability and trackability. The inner shaft has a consistent 0.021” I.D. from the luer to the tip to maximize flow and embolic delivery.


Ergonomic Handle: The handle was optimized to fit in the IR physician’s hand for constant single-handed use while allowing the other hand to manipulate a wire or other devices. With this intuitive design, the physician can easily deflect the tip in both directions and does not have to look away from the fluoroscopy screen while deflecting the tip and/or manipulating the wire.


Deflectable Tip Design: The fully covered 1.5cm tip is designed to deflect consistently up to 180 degrees in both directions (on a single plane). The distal and proximal marker bands allow physicians to see the deflection of the entire tip under fluoroscopy.

SEED-2 EXTENSION FINANCING

  • ~$1.15m target extension of Seed-2 financing

  • Preferred equity shares

  • $7.5m pre-money valuation, ~$10m post-money valuation (including ~$1.35m Seed-2 funds raised in Dec 2022)

  • All other terms remain unchanged from Seed-2 financing

 

LEADERSHIP TEAM
Ben Merewitz: CEO, Co-Founder, Board Director – 15+ years of strategy, management consulting, product management, corporate development, and executive leadership experience across medtech, biopharma, and industrials. MIT Sloan MBA.
Stephen Hebert: Inventor, Co-Founder – 25+ years of medical device design and founder of 5 medical device companies; Started and sold 2 neurovascular device companies to Micrus / J&J including a pull wire deflectable microcatheter called Enzo.
Leo Tsai, MD PhD MSc: Co-Founder and Medical Lead; Radiologist, Mass General Hospital; Assistant Professor of Radiology, Harvard Medical School.
Stephen Tully: V.P. of R&D – 25+ years medical device R&D experience (USCI, Bard, Covidien, Terumo, Medtronic) – Most recently developed product portfolio for Beacon Endoscopic, ultimately sold to Covidien / Medtronic.
William Gorman: Regulatory & Quality Lead (consultant) – 35+ years medical device regulatory/quality/development experience. Has shepherded dozens of devices from concept to market.


CLINICAL ADVISORY TEAM:
Muneeb Ahmed, MD: Chief, Division of Vascular and Interventional Radiology, Beth Israel Deaconess Medical Center (BIDMC). Associate Professor of Radiology, Harvard Medical School.
Ammar Sarwar, MD: Co-Director of Liver Tumor Program, Beth Israel Deaconess Medical Center (BIDMC). Assistant Professor of Radiology, Harvard Medical School.
Ajit Puri, MD: Chief, Division of Interventional Neuroradiology, UMass Memorial Medical Center (UMMMC). Professor of Radiology, Neurosurgery and Neurology, UMMMC.
Anand S. Patel, MD: Chairman of Radiology, Providence Little Company of Mary Medical Centers - Torrance & San Pedro, CA; Research Associate of Radiology, UCSF Medical Center

BOARD OF DIRECTORS
Ben Merewitz: Board Chair; Bio above.
Christopher Rich: Board Director; Angel investor, member of Launchpad Venture Group and Sky Ventures; Corporate executive, advisor, and investor in global consumer healthcare; Led GlaxoSmithKline Consumer Healthcare’s $3 billion Wellness business; Extensive track record of marketing and new product leadership roles at Gillette / Procter & Gamble. A.B. in Economics/East Asian Studies from Harvard University and MBA from the Tuck School of Business at Dartmouth.
Patrick Rivelli: Board Director; Serial medical device entrepreneur, executive and investor for 25+ years. Currently CEO of SanaHeal, former CEO of SMART Therapeutics (acquired by Boston Scientific) & Bioabsorbable Therapeutics (acquired by Multi Cell Corporation). A.B. in Economics from Harvard University and MS in Management from the MIT Sloan School. Holds 9 issued patents.
Will Iselin: Board Observer/Advisor; Angel investor, member of Launchpad Venture Group. Experienced corporate executive, private company investor and corporate financier in the UK and the US, with decades of investment banking and transactional experience. Shareholder/director in many private companies. A.B. in History from Harvard University. 4-time US NCAA Squash Champion.
Stephen Tully: Board Observer/Advisor; Bio above.

LUPII

AGILE DEVICES

CEO/CO-FOUNDER

20221117 Agile - Merewitz.jpg

BEN MEREWITZ

 

Ben Merewitz brings over 15 years of experience launching and managing
businesses in industrials, biopharma and medical technology. Prior to Agile
Devices, Ben spent most of his career advising management teams and
launching products in high-tech sectors with heavy regulatory oversight. From
building and scaling the first solar inverter market research practice to
advising global publicly traded biopharma companies on multibillion dollar
decisions, Ben has consistently delivered strategic value to the C-suite, either
as an external consultant or an internal advisor or Chief of Staff. As an
operator, Ben has designed, built, and scaled products and services ranging
from aviation mobile applications to APAC-focused biotech consultancies,
consistently delivering 7+ figure revenue in the first year following launch.
Ben has excelled in emerging/midsize companies (PureSense, PHOTON
Consulting, Sentient Jet) and large multinational companies (Wellington
Management, Alexion Pharmaceuticals, DRG and Clarivate), with functional
responsibilities primarily in corporate development, product management, and
management consulting. Ben holds a BA in Psychology from Amherst College
and MBA in General Management from MIT Sloan.

PAST SYNDICATED COMPANIES

20221117 Agile Devices HIRES_edited
20240229 WURQ Logo1
20240201 Nuvio Mobility
20231219 pente_logo
20221011 Moxie_Scrubs_Logo NEW_edited
20230727 Mercator logo
20230715 Fuego logo
20230323 Measure Studio logo hi-res 300X90
20230126 Avadain Logo tm
20210614 MomiBaby logo cropped
20221201 EarthGrid_COLOR 200X50
20221117 Agile Devices HIRES_edited
20221110 Epilogue Systems logo
20221011 Moxie_Scrubs_Logo NEW_edited
20220922 TANG app 400X210
20220908 Beckon-FullLogo 400X252
20220531 SurgiBox logo 200X133
20220523 Alleviate-Therapy 200X
20220425 egs-logo
20220413 Eunimart logo 300X
20220201 Lingrove
20210906 Moxie_Scrubs_Logo 500X135
20210819 Landsdowne Labs
20210722 RocketStar
20210614 MomiBaby logo cropped
20210527 Cognoptix logo 200X36
20210427 Synd Call LUPII_LOGO 200X
20210121 TANG app 2 150X
20201209 Wave logo 200X
20201203 Beckon logo
20201119%20Syndication%20Dover%20Microsy
20200826 New View logo
20200813%2520COLORONLY%2520logo_edited_e
20200811 BrightSpec Logo
unnamed
Wheeli
Vaporox
Cargo Chief
MyndBlue
Health Hero
agencyQ
HIPAAtrek
IrriGreen
SIA
Tire Agent
Wibmo

HOW IT WORKS

Use arrows on the side to navigate

1. HOST CHAPTER

A company must meet a threshold of member investment in one of our HBS Alumni Angel Chapters listed here. The leadership of the host chapter nominates the company for global syndication and provides a local member contact to act as syndication lead and a company contact.

CRITERIA

Ideally, for global syndication a company should meet the following requirements:

  • Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication; 

  • Company assures at least $50,000-100,000 investible capacity;

  • Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;

  • Minimum individual investment amount is set at $25,000 or less;

  • Company agrees to a one-time admin fee of $1500.

The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars. 

*NY and other larger chapters may have a $100,000 min.

bottom of page